Comparison of Leukapheresis Products from Patients with AML and ALL Suggests Increased T-cell Exhaustion Among Patients with AML (TCT-ASTCT-CIBMTR 2026) - Jan 8, 2026 - Abstract #844; 629; Pres time: Feb 5, 2026; 06:30 PM - 08:00 PM; Location: Hall AB (Salt Palace Convention Center); P1/2 | "We observed only transient expansion of CAR T-cells in 9 of 19 children, adolescents, and young adults infused in CD33-targeted CAR T-cells (CD33CART) in our recently completed phase I clinical trial (NCT03971799), with complete response occurring in only 2 subjects. A trend towards increased T-cell exhaustion in AML patient-origin products was observed and merits evaluation in larger studies to understand potential contribution to poor CAR T-cell functionality in patients with r/r AML. To describe disparity in outcomes between CAR T-cells for AML (acute myeloid leukemia) and B-ALL (B-cell acute lymphoblastic leukemia) To compare T-cell immunophenotypes and monocyte subsets in leukapheresis products from patients with AML, ALL, or healthy donors To discuss the potential role of leukapheresis composition in CAR T-cell efficacy"
Clinical • IO biomarker • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • B Acute Lymphoblastic Leukemia • CD4 • CD69 • CD8 • ENTPD1 • HAVCR2 • IL2RA • IL7R • LAG3 • SELL
|
|
Alexandra Dreyzin, MD MS 1; Joseph Rocco, MD 2; Anna Cantilena, BS 3; Avani Kelekar, BS 4; Kyu Lee Han, Ph. D. 5; Sarah K Tasian, MD 6; Richard Aplenc, MD, PhD 7; Steven M Devine, MD 8; Ping Jin, MD 9; David F. Stroncek, MD 10; Nirali N. Shah, MD, MHSc 1
|